Risk stratification by considering history of thrombosis, JAK2 and MPL mutations, and age can be beneficial, and treatment can be planned accordingly.16 Treatment for essential thrombocytosis includes cytoreductive therapy with hydroxyurea. This evidence concerns the gene JAK2 and Venous thrombosis.